Why the Michael J. Fox Foundation Advocates for Cannabis Research

JULIA TRAVERS | October 23, 2019 | 131 views

The Michael J. Fox Foundation for Parkinson’s Research (MJFF), which was established by and is named after the actor who has the disease, continues to advocate for cannabis research. As reported by Marijuana Moment, the group is currently pushing Congress to pass three bills relating to cannabis research and medical marijuana; the Medical Cannabis Research Act, VA Medicinal Cannabis Research Act and Expanding Cannabis Research and Information Act.  “Our role on the public policy team is to work with Congress and the administration to ensure there is access and funding for research and care initiatives that can benefit people living with Parkinson’s and, right now, that includes access to medical cannabis for research,” Ted Thompson, the foundation’s senior vice president of public policy, said. According to the MJFF site, the public policy team is currently tracking these bills and aims to inform members of Congress and their staff as to why the bills matter to the Parkinson’s community.

Spotlight

Abgent, a WuXi AppTec company

Abgent, a WuXi AppTec company, is a leading manufacturer of primary antibodies with more than a decade of experience. We meet the ever changing demands of research and drug discovery through a thoughtful target selection process and strengthened validation-standards. Moreover, we strive to continuously improve the customer experience through comprehensive technical support, a world class website, and an easy ordering process.

OTHER ARTICLES
MedTech

Top 10 biotech IPOs in 2019

Article | July 13, 2022

The big question at the start of 2019 was whether the IPO window would stay open for biotech companies, particularly those seeking to pull off ever-larger IPOs at increasingly earlier stages of development. The short answer is yes—kind of. Here’s the long answer: In the words of Renaissance Capital, the IPO market had “a mostly good year.” The total number of deals fell to 159 from 192 the year before, but technology and healthcare companies were standout performers. The latter—which include biotech, medtech and diagnostics companies—led the pack, making up 43% of all IPOs in 2019. By Renaissance’s count, seven companies went public at valuations exceeding $1 billion, up from five the year before

Read More
MedTech

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | July 12, 2022

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More
Medical

Closing bacterial genomes from the human gut microbiome using long-read sequencing

Article | August 16, 2022

In our lab, we focus on the impact of the gut microbiome on human health and disease. To evaluate this relationship, it’s important to understand the particular functions that different bacteria have. As bacteria are able to exchange, duplicate, and rearrange their genes in ways that directly affect their phenotypes, complete bacterial genomes assembled directly from human samples are essential to understand the strain variation and potential functions of the bacteria we host. Advances in the microbiome space have allowed for the de novo assembly of microbial genomes directly from metagenomes via short-read sequencing, assembly of reads into contigs, and binning of contigs into putative genome drafts. This is advantageous because it allows us to discover microbes without culturing them, directly from human samples and without reference databases. In the past year, there have been a number of tour de force efforts to broadly characterize the human gut microbiota through the creation of such metagenome-assembled genomes (MAGs)[1–4]. These works have produced hundreds of thousands of microbial genomes that vastly increase our understanding of the human gut. However, challenges in the assembly of short reads has limited our ability to correctly assemble repeated genomic elements and place them into genomic context. Thus, existing MAGs are often fragmented and do not include mobile genetic elements, 16S rRNA sequences, and other elements that are repeated or have high identity within and across bacterial genomes.

Read More

Selexis Cell Line Development Strategies

Article | February 11, 2020

In today’s biotechnology landscape, to be competitive, meet regulations, and achieve market demands, “we must apply Bioprocessing 4.0,” said Igor Fisch, PhD, CEO, Selexis. In fact, in the last decade, “Selexis has evolved from cloning by limiting dilution to automated cell selection to nanofluidic chips and from monoclonality assessment by statistical calculation to proprietary bioinformatic analysis,” he added. Single-use processing systems are an expanding part of the biomanufacturing world; as such, they are a major component of Bioprocessing 4.0. “At Selexis, we use single use throughout our cell line development workflow. Currently, we have incorporated single-use automated bioprocessing systems such as ambr® and the Beacon® optofluidic platform for accelerated cell line development. By using these systems and optimizing our parameters, we were able to achieve high titers in shake flasks. Additionally, the Beacon systems integrate miniaturized cell culture with high-throughput liquid handling automation and cell imaging. This allows us to control, adjust, and monitor programs at the same time,” noted Fisch.

Read More

Spotlight

Abgent, a WuXi AppTec company

Abgent, a WuXi AppTec company, is a leading manufacturer of primary antibodies with more than a decade of experience. We meet the ever changing demands of research and drug discovery through a thoughtful target selection process and strengthened validation-standards. Moreover, we strive to continuously improve the customer experience through comprehensive technical support, a world class website, and an easy ordering process.

Related News

The Power of Cannabis Hairs Revealed With Microscopy, Genetic Testing

LabRoots | November 01, 2019

A recent study from the University of British Columbia, published in The Plant Journal examined the hairs, or glandular trichomes, of cannabis plants. The structures and chemical outputs of various hairs were studied through microscopy and chemical profiling. The plant sample used was a quick-flowering variety of hemp Cannabis sativa known as “Finola.” The largest and mushroom-shaped “stalked” plant hairs were discovered to be the most potent; they produced the most THC- and CBD-forming metabolites and scent-producing terpenes. This fact has been previously suspected but unproven within the cannabis community. Earlier studies categorized the cannabis plant hairs as either bulbous, sessile or stalked, based on how they looked. But how they actually affected the strength of the plant’s effects was unknown. A gene expression analysis and UV light examinations helped the researchers to better understand the hairs’ properties. "We saw that stalked glandular trichomes have expanded ‘cellular factories’ to make more cannabinoids and fragrant terpenes. We also found that they grow from sessile-like precursors and undergo a dramatic shift during development that can be visualized using new microscopy tools,” co-lead author and Botany Ph.D. candidate Sam Livingston said.

Read More

Is There Really a Difference Between Indica and Sativa?

labroots | April 26, 2019

The idea that there are different strains, (Cannabis indica and Cannabis sativa), has almost become cannabis dogma. They look different, indicas are typically shorter and more scrub-like while sativas are taller. They came from different regions, indicas from Afghanistan and India and sativas from central America. They even are thought to have different effects. Indicas are thought to induce a sense of deep body relaxation, while sativas tend to produce an energizing experience. But is there any science to these claims? The idea that these strains are different species comes from the famous biologist Jean Baptiste Lamarck, known primarily being wrong about how species evolve. Lamark classified these strains as different species based primarily in the manner that we do today. According to an essay published by Jacob L. Erkelens and Arno Hazekamp in the journal Cannabinoids, Lamark distinguished the plant C. sativa, which was cultivated at the time, from a new variant of cannabis that grew wild in India, was thought to be a new species. In honor of the country that it came from, Lamarck called it C.indica (for India).

Read More

CanniMed Inks Canada’s First Pharmacy Cannabis Distribution Deal

biotech | March 02, 2017

This industry-leading collaboration will see CanniMed responsible for producing and delivering accredited pharmacy education programs to PharmaChoice pharmacists and pharmacy technicians across Canada. In addition, CanniMed and PharmaChoice intend to enter a definitive agreement for distribution of medical cannabis through PharmaChoice pharmacists in Canada upon completion of the first provincial legislation change that allows such distribution

Read More

The Power of Cannabis Hairs Revealed With Microscopy, Genetic Testing

LabRoots | November 01, 2019

A recent study from the University of British Columbia, published in The Plant Journal examined the hairs, or glandular trichomes, of cannabis plants. The structures and chemical outputs of various hairs were studied through microscopy and chemical profiling. The plant sample used was a quick-flowering variety of hemp Cannabis sativa known as “Finola.” The largest and mushroom-shaped “stalked” plant hairs were discovered to be the most potent; they produced the most THC- and CBD-forming metabolites and scent-producing terpenes. This fact has been previously suspected but unproven within the cannabis community. Earlier studies categorized the cannabis plant hairs as either bulbous, sessile or stalked, based on how they looked. But how they actually affected the strength of the plant’s effects was unknown. A gene expression analysis and UV light examinations helped the researchers to better understand the hairs’ properties. "We saw that stalked glandular trichomes have expanded ‘cellular factories’ to make more cannabinoids and fragrant terpenes. We also found that they grow from sessile-like precursors and undergo a dramatic shift during development that can be visualized using new microscopy tools,” co-lead author and Botany Ph.D. candidate Sam Livingston said.

Read More

Is There Really a Difference Between Indica and Sativa?

labroots | April 26, 2019

The idea that there are different strains, (Cannabis indica and Cannabis sativa), has almost become cannabis dogma. They look different, indicas are typically shorter and more scrub-like while sativas are taller. They came from different regions, indicas from Afghanistan and India and sativas from central America. They even are thought to have different effects. Indicas are thought to induce a sense of deep body relaxation, while sativas tend to produce an energizing experience. But is there any science to these claims? The idea that these strains are different species comes from the famous biologist Jean Baptiste Lamarck, known primarily being wrong about how species evolve. Lamark classified these strains as different species based primarily in the manner that we do today. According to an essay published by Jacob L. Erkelens and Arno Hazekamp in the journal Cannabinoids, Lamark distinguished the plant C. sativa, which was cultivated at the time, from a new variant of cannabis that grew wild in India, was thought to be a new species. In honor of the country that it came from, Lamarck called it C.indica (for India).

Read More

CanniMed Inks Canada’s First Pharmacy Cannabis Distribution Deal

biotech | March 02, 2017

This industry-leading collaboration will see CanniMed responsible for producing and delivering accredited pharmacy education programs to PharmaChoice pharmacists and pharmacy technicians across Canada. In addition, CanniMed and PharmaChoice intend to enter a definitive agreement for distribution of medical cannabis through PharmaChoice pharmacists in Canada upon completion of the first provincial legislation change that allows such distribution

Read More

Events